Health Care • Biotechnology: Pharmaceutical Preparations
$26.29 ▼ -0.06
(-0.23%)
MKT CAP: $1.70B • VOL: 1.86M
52W L $20 52W H $40
STOK // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $184.4M | $36.6M | $8.8M |
| YoY Revenue Growth % | +404.5% | +316.3% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$20.6M | -$101.4M | -$114.8M |
| Operating Margin % | -11.2% | -80.0% | -80.0% |
| Net Income (GAAP) | -$6.9M | -$89.0M | -$104.7M |
| EBITDA (Normalized) | -$20.1M | -$101.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $45.6M | -$86.9M | -$81.1M |
| Capital Expenditures (CapEx) | $670.0K | $203.0K | — |
| Free Cash Flow (FCF) | $44.9M | -$87.1M | -$81.1M |
| FCF Margin % | 24.4% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -6.1% | -45.0% | — |
| Cash & Short-Term Equivalents | $84.2M | $128.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $352.5M | $229.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR STOK.